Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canvaxin + BCG in Resected Stage IV Melanoma
NCT00052156Phase 3Unknown
- Sponsor
- CancerVax
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Canvaxin + BCG with Placebo + BCG (2 arms). Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
CANVAXIN
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00052156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052156.